Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities

Journal of Clinical Oncology

Volumn 21, Issue 2, 2003, Pages 251-255

  Buckner, Jan C ^a   Gesme Jr , Dean ^a   O'Fallon, Judith R ^a   Hammack, Julie E ^a   Stafford, Scott ^a   Brown, Paul D ^a   Hawkins, Roland ^a   Scheithauer, Bernd W ^a   Erickson, Bradley J ^a   Levitt, Ralph ^a   Shaw, Edward G ^a   Jenkins, Robert ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMUSTINE; PROCARBAZINE; PROTEIN P53; VINCRISTINE; ANTINEOPLASTIC AGENT; PCV PROTOCOL;

ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR REGRESSION; ADJUVANT THERAPY; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; FEMALE; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOMUSTINE; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROCARBAZINE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; VINCRISTINE;

EID: 0037440219     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.023     Document Type: Article

References (15)

1. Vandenberg SR, Sampaio Lopez MB: Classification, in Berger MS, Wilson CB (eds): The Gliomas. Philadelphia, PA, WB Saunders, 1999, pp 172-191
2. Shaw E, Arusell R, Scheithauer B, et al: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267-2276, 2002
3. Karim ABMF, Maat B, Hatlevoll R, et al: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36:549-556, 1996
4. Karim ABMF, Cornu P, Bleehen N: Immediate postoperative radiotherapy in low-grade glioma improves progression-free, but not overall survival: Preliminary results of an EORTC/MRC randomized phase III study. Proc Am Soc Clin Oncol 17:400a, 1998 (abstr 1544)
5. Cairncross G, MacDonald D, Ludwins S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994
6. Buckner JC, Brown LD, Kugler JW, et al: Phase II evaluation of recombinant interferon-alfa and BCNU in recurrent glioma. J Neurosurg 82:430-435, 1995
7. Mason WP, Krol GS, de Angelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46:203-207, 1996
8. Smith JS, Perry A, Borell TJ, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas. astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
9. Smith JS, Tachibana I, Lee HK, et al: Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 29:16-25, 2000
10. Cunningham JM, Kimmel DW, Scheithauer BW, et al: Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J Neurosurg 86:121-130, 1997
11. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
12. Yung WK, Prados MD, Yaga-Tur R, et al: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762-2771, 1999
13. Brown PD, Buckner JC, Brown CA, et al: The effects of radiation on cognitive function in patients with low-grade glioma. Proc Am Soc Clin Oncol 20:58a, 2001 (abstr 229)
14. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
15. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845, 2001